RxDoctor Payments Data

Julie Bavin, NP

Family · Orlando, FLNPI 1023481025

Payments from drug & device makers

$469in general payments, 2019–2025

Across 25 payments — averaging $18.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$101
  • GSK$100
  • Abbott$51
  • Novo Nordisk$51
  • Exact Sciences$40
  • Lilly USA, LLC$38
  • plus $88 from 4 others

What the payments were for

  • Food & beverage$469100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca5$101
GSK7$100
Abbott2$51
Novo Nordisk2$51
Exact Sciences2$40
Lilly USA, LLC2$38
Novartis2$34
Bayer1$22
Pfizer1$17
AbbVie1$15

How this compares

$469 in reported general payments places this provider in the 55th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$12,798
Medicare patients
99
Services billed
289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide59$73,059
EliquisApixaban40$49,474
JardianceEmpagliflozin25$31,451
XareltoRivaroxaban18$19,899
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$14,281
LinzessLinaclotide11$6,630
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,873
VascepaIcosapent Ethyl12$2,835
Celecoxib24$2,333
Gabapentin110$1,627
Albuterol Sulfate HfaAlbuterol Sulfate58$1,505
Atorvastatin Calcium170$1,135
Levothyroxine Sodium107$1,126
Pantoprazole Sodium67$932
Losartan Potassium138$896

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$51$73,05959 claims
PfizerEliquis$17$49,47440 claims
GSKTrelegy Ellipta$100$14,28111 claims
AbbVieLinzess$15$6,63011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 14,618 family providers in Florida.

Other family in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →